Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2691-2700

  McKeage, M J ^a   Raynaud, F ^a   Ward, J ^a   Berry, C ^a   O'Dell, D ^a   Kelland, L R ^a   Murrer, B ^a   Santabarabara P ^a   Harrap, K R ^a   Judson, I R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SATRAPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030742993     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2691     Document Type: Article

References (28)

1. Horwich A: Germ cell chemotherapy Br J Cancer 59:156-159, 1989
2. Neijt JP, Ten Bokkel Huinink MEL, Van Oosterom AT, et al: Long-term survival in ovarian cancer. Eur J Cancer 27:1367-1372, 1991
3. Ellis PA, Smith IE, Hardy JR, et al: Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71:366-370, 1995
4. Scheithauer W, Rosen H, Kornek G, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752-755, 1993
5. Clinch JJ, Schipper H: Quality of life assessment in palliative care, in Doyle D, Hanks GWC, MacDonald N (eds): Oxford Textbook of Palliative Medicine. Oxford, United Kingdom, Oxford University, 1993, pp 61-70
6. MacDonald N: Principles governing the use of cancer chemotherapy, in Doyle D, Hanks GWC, MacDonald N (eds): Oxford Textbook of Palliative Medicine. Oxford, United Kingdom, Oxford University, 1993, pp 105-117
7. Coates A, Abraham S, Kaye SB, et al: On the receiving end-patient perception of side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208, 1983
8. Van Hennik MB, Van Der Vijgh WJF, Klein I, et al: Human pharmacokinetics of carboplatin after oral administration. Cancer Chemother Pharmacol 23:126-127, 1989
9. Siddik ZH, Boxall FE, Goddard PM, et al: Antitumor, pharmacokinetic and toxicity studies with orally administered cisplatin. CBDCA and CHIP. Proc Am Assoc Cancer Res 25:369, 1984 (abstr 1462)
10. Giandomenico CM, Abrams MJ, Murrer BA, et al: Synthesis and reactions of a new class of orally active Pt(IV) antitumour complexes, in Howell SB (ed): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York, NY, Plenum, 1991, pp 93-100
11. Harrap KR, Murrer BA, Giandomenico C. et al: Ammine/ amine platinum(IV) dicarboxylates: A novel class of complexes which circumvent intrinsic cisplatin resistance, in Howell SB (ed): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York, NY, Plenum, 1991, pp 391-399
12. Kelland LR, Murrer BA, Abel G, et al: Ammine/amine platinum(IV) dicarboxylate complexes: A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically resistant human ovarian carcinoma cells. Cancer Res 52:822-828, 1992
13. Kelland LR, Mistry P, Abel G, et al: Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/ amine platinum(IV) dicarboxylates. Cancer Res 52:3857-3864, 1992
14. Kelland LR, Abel G, McKeage MJ: Preclinical antitumour evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drug. Cancer Res 53:2581-2586, 1993
15. McKeage MJ, Morgan SE, Boxall FE, et al: Preclinical toxicology and tissue distribution of novel oral antitumour platinum complexes: Ammine/amine platinum(IV) dicarboxylates. Cancer Chemother Pharmacol 33:497-503, 1994
16. McKeage MJ, Morgan SE, Boxall FE, et al: Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents. Br J Cancer 67:996-1000, 1993
17. McKeage MJ, Boxall F, Jones M, et al: Lack of neurotoxicity of oral bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54:629-631, 1994
18. Raynaud FI, Boxall FE, Goddard P, et al: Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16:1857-1862, 1996
19. Raynaud FI, Odell DE, Kelland LR: Intracellular metabolism of the orally active platinum drug JM216: Influence of glutathione levels. Br J Cancer 73:380-386, 1996
20. Raynaud FI, Mistry P, Donaghue A, et al: Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38:155-162, 1996
21. Poon GK, Raynaud FI, Mistry P, et al: Metabolic studies of an orally active platinum drug by liquid chromatography electrospray ionisation mass spectrometry. J Chromatogr 712:61-66, 1995
22. McKeage MJ, Kelland LR, Boxall FE, et al: Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res 54:4118-4122, 1994
23. McKeage MJ, Mistry P, Ward J, et al: A phase I and pharmacological study of an oral platinum complex (JM216): Dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36:451-458, 1995
24. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
25. Mellish KJ, Barnard CFJ, Murrer BA, et al: DNA-binding properties of novel cis- and trans platinum-based anticancer agents in two human ovarian carcinoma cell lines. Int J Cancer 62:717-723, 1995
26. Groen HJM, Smit EF, Bauer J, et al: A phase II study of oral platinum JM216 in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 15378, 1996 (abstr 1128)
27. Von Hoff DD, Schilsky R, Reichert CM, et al: Toxic effects of cis-dichlorodiammine platinum(II) in man. Cancer Treat Rep 63:1527-1531, 1979
28. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997